Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck24/7 Wall Street • 07/27/26
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Business Wire • 07/23/26
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 07/21/26
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patientsPRNewsWire • 07/17/26
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?Zacks Investment Research • 07/16/26
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and DevelopmentPRNewsWire • 07/14/26
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers SquibbThe Motley Fool • 07/14/26
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a DynastyThe Motley Fool • 07/12/26
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 07/09/26